Comparing the current results to its competitors, Cidara Therapeutics Inc reported Revenue decrease in the 3 quarter 2025 year on year by 0 %, slower than the combined decrease of the CDTX's competitors by -3.32 %, recorded in the same quarter.
Cidara Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 12.91 %
October 13, 2025
Cidara Therapeutics Set to Showcase Promising Data for CD388 at ID Week 2025 amid Challenging Financial Landscape Cidara Therapeutics, Inc. (Nasdaq: CDTX), a pioneering biotechnology company known for its innovative Cloudbreak platform responsible for advancing drug-Fc conjugate (DFC) therapeutics, is preparing to present late-breaking Phase 2 clinical data on its antiviral influenza candidate, CD388. This pivotal presentation will occur during ID Week 2025, scheduled for October 19-22, 2025, in Atlanta, Georgia.The significance of this event cannot be overstated as it represents a critical juncture for Cidara, particularly in the context of its current financial performance. The company s announcement prece...
April 24, 2024
In a recent development, Cidara Therapeutics, a biotechnology company specializing in drug-Fc conjugate (DFC) immunotherapies, has announced the divestiture of rezafungin to Mundipharman. This strategic move allows Cidara to shift its focus towards advancing the clinical development of their promising Cloudbreak DFC pipeline.Under the asset purchase agreement, Mundipharma, an existing partner of Cidara, will acquire commercial rights to rezafungin outside the United States and Japan. In return, Mundipharma assumes the responsibility to conduct and fund the ongoing ReSPECT Phase 3 clinical trial, as well as cover the costs associated with the rezafungin patent portfolio and CMC (chemistry, manufacturing, and ...
Gilead Sciences Incs business model centers on researching, developing, and marketing innovative medicines, primarily targeting antiviral therapies. They focus on addressing unmet medical needs to enhance patient health globally.
Amphastar Pharmaceuticals Inc's business model revolves around developing, manufacturing, and marketing specialty pharmaceutical products. The company focuses on niche markets and primarily produces finished dosage form and active pharmaceutical ingredients (APIs) for injectable, inhalation, and intranasal delivery systems. Amphastar aims to provide innovative and cost-effective solutions for complex therapeutic needs, while maintaining regulatory compliance and ensuring the highest standard of quality.
Atea Pharmaceuticals Inc. is a biopharmaceutical company that focuses on developing antiviral therapeutics to combat infectious diseases. Their business model revolves around identifying and advancing novel drug candidates that target specific viral mechanisms and inhibit their replication. This includes conducting preclinical and clinical trials, engaging in strategic partnerships, and ultimately bringing effective antiviral treatments to market.
AstraZeneca Plc is a global biopharmaceutical company focused on the research, development, and commercialization of innovative medicines. Their business model involves investing extensively in research and development to discover novel treatments for a wide range of diseases. AstraZeneca then markets and sells these medicines globally, collaborating with healthcare providers and leveraging their strong sales and distribution networks.
Pfizer Inc operates as a global pharmaceutical company that focuses on researching, developing, manufacturing, and marketing innovative medicines. Its business model emphasizes significant investment in research and development to build a diverse portfolio of therapies across various therapeutic areas, while leveraging strategic alliances and collaborations to enhance commercialization and drive growth.
Sources:
Cidara Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cidara Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
